France Erythropoietin Drugs Market Report 2023 to 2030

France Erythropoietin Drugs Market Analysis

$ 3999

France Erythropoietin Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for erythropoietin drugs is growing rapidly as a result of rising prevalence of chronic diseases like kidney diseases, cancer, HIV globally and requirements of erythropoietin drugs in these diseases, rise in anemia in patients, growing awareness about blood related disorders like anemia, patent expiration of innovator drugs and development of generic drugs, development of erythropoietin biosimilars and therapeutic benefits offered by erythropoietin drugs. Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Celltrion, Inc., and Biocon Limited are the key market players operating in global erythropoietin drugs market.

ID: IN10FRRD083 CATEGORY: Rare Diseases GEOGRAPHY: France AUTHOR: Nipun Arora

Buy Now

France Erythropoietin Drugs Market Analysis Summary

France Erythropoietin Drugs Market is valued at around $0.286 Bn in 2022 and is projected to reach $0.411 Bn by 2030, exhibiting a CAGR of 4.65% during the forecast period 2023-2030.

A hormone that controls growth and promotes the creation of red blood cells is erythropoietin. The bone marrow produces red blood cells, which aid in distributing oxygen throughout the body. Drugs containing erythropoietin are used to treat anaemia caused by HIV, cancer treatment (chemotherapy-induced anaemia), or chronic kidney disease. There are numerous erythropoietin medication varieties available. Epogen was the first blockbuster biologic for anaemia developed by Amegen approved by the FDA and is still widely used. Erythropoietin biosimilars are projected to gain major market share in future because of their cheap prices and therapeutic advantages offered by them. Antioxidant signalling pathways, neurogenesis, and anti-inflammatory signalling pathways therapeutic advantages have all been demonstrated by erythropoietin drug treatment. Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Celltrion, Inc., and Biocon Limited are the key market players operating in global erythropoietin drugs market.

Market Dynamics

Market Drivers

Increase in incidence and prevalence of chronic diseases leading to anaemia- Chronic diseases like chronic kidney disease, cancer and HIV act as market growth drivers.

Increase in awareness about blood-related diseases – Government programmes and support from various nongovernmental organizations has led to an increase in blood-related diseases globally which acts as a market growth driver.

Patent expiration of innovator drugs – Due to the expiration of patents of innovator drugs generic drugs are being developed by pharmaceutical companies which acts as a market growth driver.

EPO Biosimilars: The market has been severely impacted by the introduction of biosimilar versions of erythropoietin medications. The reference biologic medicine (originator) has biosimilars available as a more reasonably priced alternative because they are very comparable to it. Erythropoietin biosimilars' accessibility has encouraged competition, resulting in lower prices and wider access to treatment and thus a market growth driver.

Development of Technology – Recombinant DNA technology used in the development of biosimilars also acts as a market growth driver.

Therapeutic benefits associated with erythropoietin drugs – These drugs provide other therapeutic benefits like improving neuroplasticity and cognitive functions of the brain and activating anti-inflammatory pathways. This also acts as a market growth driver.

Market Restraints

Adverse effects caused by erythropoietic agents – Adverse effects like myocardial infarction and ischemic stroke are associated with these drugs which acts as a market growth restraint.

Higher Prices of erythropoietin drugs – This acts as a market growth restraint, particularly in developing and underdeveloped nations.

Reimbursement issues – Government reimbursement policies and insurance coverage limitations can also act as market growth restraints.

Key players

Amgen Janssen Sandoz Pfizer Sanofi Hospira Baxter International Kedrion Biopharma Octapharma Grifols

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For France Erythropoietin drugs market

By Drug Type

Biologics
Biosimilars

By Drugs

Epoetin-Alfa
Darbepoetin-Alfa
Epoetin-Beta
Others

By Indication

Cancer
Neurology
Hematology
Renal diseases
Others

By Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

By End-Users

Hospitals
Homecare
Speciality Centres
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.